お知らせ • Mar 02
NovAccess Global Inc., Annual General Meeting, May 06, 2024 NovAccess Global Inc., Annual General Meeting, May 06, 2024, at 12:00 US Eastern Standard Time. お知らせ • Nov 11
NovAccess Global Inc. Appoints Roscoe M. Moore, Jr. to Scientific Advisory Board NovAccess Global Inc. announced the appointment of Dr. Roscoe M. Moore, Jr., to its Scientific Advisory Board. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General. The addition of Dr. Moore brings the NovAccess Global Scientific Advisory Board to 6 members. NovAccess Global intends to leverage the expertise, insight and professional network of Dr. Moore with NIH and other healthcare centers of influence toward accessing government non-dilutive funding, including the White House Cancer Moonshot, amongst other targeted award mechanisms. Dr. Moore will be tapped to assist NovAccess Global to develop collaborations here in the US and overseas. Through Dr. Moore, NovAccess Global will strive to initiate publicly facilitated studies for immune suppressed patients, who are at higher risk for glioblastoma and other cancers. Dr. Moore served with the United States Department of Health and Human Services (HHS) and was for the last twelve years of his career responsible for global development within the Office of the Secretary, HHS, for Africa and other low- and middle-income regions. Dr. Moore represented HHS in cooperative international efforts in Africa to address continued health and human resources issues. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General (Rear Admiral, USPHS) within the Immediate Office of the Secretary, HHS. He was selected as Chief Veterinary Medical Officer, USPHS, by Surgeon General C. Everett Koop. Dr. Moore received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Tuskegee Institute; his Master of Public Health degree in Epidemiology from the University of Michigan; and his Doctor of Philosophy degree in Epidemiology from the Johns Hopkins University. He was awarded the Doctor of Science degree (Honoris Causa) in recognition of his distinguished public health career by Tuskegee University. お知らせ • Nov 11
Novaccess Global Inc. Appoints Peter Weinstein to Scientific Advisory Board NovAccess Global Inc. announced the appointment of Peter Weinstein, PH.D., JD to its Scientific Advisory Board. Dr. Weinstein is a well-regarded intellectual property attorney and healthcare industry consultant who has been serving as legal counsel to NovAccess Global subsidiary StemVax Therapeutics for several years. With the addition of Dr. Weinstein, the NovAccess Global Scientific Advisory Board has five members, with disciplines spanning biotechnology and medical technology IP, healthcare IT, U.S. government agency and grant submissions, oncology drug development, and clinical research. Peter D. Weinstein, Ph.D., J.D counsels in all aspects of intellectual property, transaction and corporate law. He is the founder and Chief Executive Officer of Entralta, an intellectual property management company driven to bring the high quality of work to its clients by focusing on each client's needs. In addition, he is the chief legal counsel to NovAccess Global subsidiary StemVax Therapeutics. Dr. Weinstein received his Juris Doctorate degree at Boston College Law School, and is registered patent attorney licensed to practice law in California and Texas and is admitted to U.S. District Courts located in California and Texas. He also received a Ph.D. in Biology with an emphasis in Immunology from the University of Pennsylvania. Following receipt of his Ph.D., Dr. Weinstein worked as a Research Fellow, first at the National Institutes of Health in Bethesda, Maryland and then at the United States Army Medical Research Institute of Infectious Disease in Frederick, Maryland where he investigated the molecular development of antibody diversity and worked on vaccine development. Prior to forming Entralta, Dr. Weinstein worked for many years as Senior Patent Counsel at Baxter Healthcare Corporation where he was responsible for managing legal and intellectual property matters for Baxter's major hemophilia products like Advate® and major research and development programs in hemophilia that led to the approval by the FDA of Adenovate® and VonVendi®. This work entailed working with multidisciplinary teams in the United States, Europe, and Asia. Earlier, Dr. Weinstein worked in the San Diego Offices of the law firms of Brobeck, Phleger & Harrison, and Fish & Richardson where his practice focused on the management and prosecution of patent portfolios for biotech and high tech companies and patent and general civil litigation. During law school, he worked full-time as a patent agent in the Boston Office of Goodwin Procter. Dr. Weinstein also worked as an Examiner at the United States Patent and Trademark Office followed by a stint as a Senior Scientist at a biotech company where he was responsible for the Animal Health Group developing vaccines and other therapeutics for the treatment of infectious disease in large animals. お知らせ • Nov 10
NovAccess Global Inc., Annual General Meeting, Nov 21, 2022 NovAccess Global Inc., Annual General Meeting, Nov 21, 2022, at 11:00 US Eastern Standard Time. Agenda: To consider and review the customary shareholder voting procedures and an investor presentation to be provided by the Company's management; and to discuss any other matters. お知らせ • Feb 03
NovAccess Global Inc. Announces Board Changes On January 31, 2022, NovAccess Global Inc. (‘NovAccess’) entered into a preferred stock redemption agreement (‘Agreement’) with TN3, LLC (‘TN3’), Mr. Daniel G. Martin, Irvin Consulting, LLC (‘IC’), and Dr. Dwain Morris-Irvin. Mr. Martin is the company's chairman of the board and owns TN3. Dr. Irvin is the company's chief executive officer and owns IC. Upon completion of the redemption, Mr. Martin will resign from the NovAccess board and be replaced by Dr. Irvin and John Cassarini. お知らせ • Oct 29
Novaccess Global Inc. Announces Executive Changes NovAccess Global Inc. announced that L. Michael Yukich joined as fractional chief financial officer, replacing Daniel G. Martin, who had been serving as interim CFO. Mr. Martin remains chairman of the board of directors. Mike Yukich, age 74, has extensive financial and accounting experience and for the past twenty years he has held the position of chief financial officer for both public and private companies. Mr. Yukich currently serves as interim chief financial officer for Innovest Global Inc. Mr. Yukich served as Innovest’s CFO from August 2017 to October 2019 and rejoined the company in September 2020.